R01AI165080

HIV-1 Q23.17 Env: Engineering a Novel Immunogen to Elicit Broadly Neutralizing Antibodies - Project Summary

In humans, neutralizing antibodies elicited by HIV-1 coevolve with viral Envs in distinctive patterns, in some cases acquiring substantial breadth. We found that primary HIV-1 Envs, when expressed by simian-human immunodeficiency viruses (SHIVs) in 22 rhesus macaques (RMs), elicited patterns of Env-Ab coevolution strikingly similar to those in humans (Science 371:eabd2638, 2021).

This included conserved immunogenetic, structural, and chemical solutions to epitope recognition and precise Env-amino acid substitutions, insertions, and deletions leading to virus persistence. The structure of one rhesus antibody, capable of neutralizing 49% of a 208-strain panel, revealed a V2-apex mode of recognition like that of human broadly neutralizing antibodies (bNAbs) PGT145 and PCT64.

We subsequently expanded this study to include 150 RMs infected by SHIVs bearing any of 15 different primary HIV-1 Envs; 24 (16%) of these animals developed bNAbs targeting conserved V2-apex, V3-glycan, CD4-binding site (CD4BS), or fusion peptide epitopes. The V2-apex was the most common bNAb epitope targeted in RMs.

We concluded that Env-Ab coevolution in RMs recapitulates developmental features of human bNAbs and may serve to guide and accelerate HIV-1 immunogen design for humans. From these preclinical data, we identified HIV-1 Q23.17 Env as the immunogen that most consistently elicited V2-apex bNAbs.

Here, we propose to elucidate the Env-Ab coevolutionary pathways by which HIV-1 Q23.17 Env selectively primes, boosts, and affinity-matures V2-apex bNAb responses and to translate these findings into an all-SOSIP Env trimer vaccine regimen consisting of a germline-targeted Q23.17 Env prime followed by boosts with lineage-designed Q23.17 Env "imunotypes" capable of affinity-maturing B cells to achieve breadth.

Specific aims are:
(I) To decipher molecular pathways of Env-Ab coevolution in SHIV.Q23.17 infected RMs that lead to the development of V2-apex bNAbs, including the identification of inferred germline bNAb precursors and lineage intermediates and corresponding Env immunotypes that bind to them;
(II) To use mammalian display saturation mutagenesis to generate Q23.17 Env variants that exhibit enhanced binding affinity to multiple rhesus germline V2-apex bNAb B cell precursors and to engineer these Envs as nanoparticle-delivered SOSIP trimers;
(III) To test the immunogenicity of germline-targeted and lineage-designed Q23.17 Env SOSIP trimers in V2-apex bNAb UCA knockin mice and outbred RMs and to advance the most promising combinations to a proof-of-concept preclinical vaccine trial in RMs; and
(IV) To conduct an appropriately powered preclinical vaccine trial in 28 RMs to test the hypothesis that reverse-engineered, lineage-designed Q23.17 SOSIP Env trimers can prime, boost, and affinity mature V2-apex bNAb responses in RMs to an extent that is superior to conventional SOSIP Env immunogens and that protects RMs from heterologous virus challenge.

The significance of these studies could be far-reaching: if we can demonstrate consistent induction of bNAbs using germline-targeted, lineage-designed Q23.17 Env SOSIPs in RMs, it would represent a new beachhead for HIV-1 vaccine research that could be translated rapidly into human clinical trials.

Trustees Of The University Of Pennsylvania

TO ASSIST PUBLIC AND PRIVATE NONPROFIT INSTITUTIONS AND INDIVIDUALS TO ESTABLISH, EXPAND AND IMPROVE BIOMEDICAL RESEARCH AND RESEARCH TRAINING IN INFECTIOUS DISEASES AND RELATED AREAS, TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS. TO ASSIST PUBLIC, PRIVATE AND COMMERCIAL INSTITUTIONS TO CONDUCT DEVELOPMENTAL RESEARCH, TO PRODUCE AND TEST RESEARCH MATERIALS, TO PROVIDE RESEARCH SERVICES AS REQUIRED BY THE AGENCY FOR PROGRAMS IN INFECTIOUS DISEASES, AND CONTROLLING DISEASE CAUSED BY INFECTIOUS OR PARASITIC AGENTS, ALLERGIC AND IMMUNOLOGIC DISEASES AND RELATED AREAS. PROJECTS RANGE FROM STUDIES OF MICROBIAL PHYSIOLOGY AND ANTIGENIC STRUCTURE TO COLLABORATIVE TRIALS OF EXPERIMENTAL DRUGS AND VACCINES, MECHANISMS OF RESISTANCE TO ANTIBIOTICS AS WELL AS RESEARCH DEALING WITH EPIDEMIOLOGICAL OBSERVATIONS IN HOSPITALIZED PATIENTS OR COMMUNITY POPULATIONS AND PROGRESS IN ALLERGIC AND IMMUNOLOGIC DISEASES. BECAUSE OF THIS DUAL FOCUS, THE PROGRAM ENCOMPASSES BOTH BASIC RESEARCH AND CLINICAL RESEARCH. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM EXPANDS AND IMPROVES PRIVATE SECTOR PARTICIPATION IN BIOMEDICAL RESEARCH. THE SBIR PROGRAM INTENDS TO INCREASE AND FACILITATE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. THE SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM STIMULATES AND FOSTERS SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. RESEARCH CAREER DEVELOPMENT AWARDS SUPPORT THE DEVELOPMENT OF SCIENTISTS DURING THE FORMATIVE STAGES OF THEIR CAREERS. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARDS (NRSAS) ARE MADE DIRECTLY TO APPROVE APPLICANTS FOR RESEARCH TRAINING IN SPECIFIED BIOMEDICAL SHORTAGE AREAS. IN ADDITION, INSTITUTIONAL NATIONAL RESEARCH SERVICE AWARDS ARE MADE TO ENABLE INSTITUTIONS TO SELECT AND MAKE AWARDS TO INDIVIDUALS TO RECEIVE TRAINING UNDER THE AEGIS OF THEIR INSTITUTIONAL PROGRAM.

93.855 - Allergy and Infectious Diseases Research

National Institute of Allergy and Infectious Diseases (NIAID) [HHS - NIH]

Philadelphia, Pennsylvania 19104 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-20-185)

Amendment Since initial award the total obligations have increased 544% from $803,267 to $5,173,076.